Literature DB >> 23952252

Neonatal Fc receptor and its role in the absorption, distribution, metabolism and excretion of immunoglobulin G-based biotherapeutics.

Craig Giragossian1, Tracey Clark, Nicole Piché-Nicholas, Christopher J Bowman.   

Abstract

The neonatal Fc receptor (FcRn) is a heterodimeric membrane associated protein expressed in a variety of endothelial, epithelial and hematopoietic cells. FcRn regulates pH dependent intracellular trafficking of immunoglobulin G (IgG) and albumin, resulting in enhanced serum persistence and transcellular permeability of these proteins compared to other proteins of similar size. FcRn confers passive immunity during the early stages of life by facilitating maternal transmission of antibodies during gestation, and in some species during the neonatal period. The receptor continues to contribute to immunity beyond the perinatal period and throughout life by providing immunosurveillance in intestinal, pulmonary and genitourinary mucosa. In this capacity, FcRn facilitates bidirectional transport of IgG across mucosa and intracellular trafficking of antigen-antibody complexes in antigen presenting cells. Based on the functional roles of FcRn in regulating serum persistence and transcellular permeability, protein engineers have sought to exploit this receptor as a means of enhancing the absorption, distribution, metabolism and excretion (ADME) of IgG-based therapeutics. In this review, the current state of knowledge regarding the structural, mechanistic and functional properties of FcRn, as they relate to the ADME of IgG-based therapeutics, are discussed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23952252     DOI: 10.2174/13892002113149990099

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  16 in total

1.  Toward in vitro-to-in vivo translation of monoclonal antibody pharmacokinetics: Application of a neonatal Fc receptor-mediated transcytosis assay to understand the interplaying clearance mechanisms.

Authors:  Claudia A Castro Jaramillo; Sara Belli; Anne-Christine Cascais; Sherri Dudal; Martin R Edelmann; Markus Haak; Marie-Elise Brun; Michael B Otteneder; Mohammed Ullah; Christoph Funk; Franz Schuler; Silke Simon
Journal:  MAbs       Date:  2017-04-25       Impact factor: 5.857

2.  Endosomal trafficking regulates receptor-mediated transcytosis of antibodies across the blood brain barrier.

Authors:  Arsalan S Haqqani; Christie E Delaney; Eric Brunette; Ewa Baumann; Graham K Farrington; William Sisk; John Eldredge; Wen Ding; Tammy-Lynn Tremblay; Danica B Stanimirovic
Journal:  J Cereb Blood Flow Metab       Date:  2017-11-15       Impact factor: 6.200

3.  Utility of immunodeficient mouse models for characterizing the preclinical pharmacokinetics of immunogenic antibody therapeutics.

Authors:  Maria Myzithras; Tammy Bigwarfe; Hua Li; Erica Waltz; Jennifer Ahlberg; Craig Giragossian; Simon Roberts
Journal:  MAbs       Date:  2016-09-06       Impact factor: 5.857

Review 4.  An update on the use of immunoglobulin for the treatment of immunodeficiency disorders.

Authors:  Stephanie Albin; Charlotte Cunningham-Rundles
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

Review 5.  Delivering safer immunotherapies for cancer.

Authors:  Lauren Milling; Yuan Zhang; Darrell J Irvine
Journal:  Adv Drug Deliv Rev       Date:  2017-05-22       Impact factor: 15.470

Review 6.  Preclinical optimization of antibody-based radiopharmaceuticals for cancer imaging and radionuclide therapy-Model, vector, and radionuclide selection.

Authors:  Lukas M Carter; Sophie Poty; Sai Kiran Sharma; Jason S Lewis
Journal:  J Labelled Comp Radiopharm       Date:  2018-03-30       Impact factor: 1.921

Review 7.  Etanercept biosimilars.

Authors:  Valderilio F Azevedo; Nathalia Galli; Alais Kleinfelder; Julia D'Ippolito; Paulo C M Urbano
Journal:  Rheumatol Int       Date:  2014-07-01       Impact factor: 2.631

Review 8.  Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters.

Authors:  William R Strohl
Journal:  BioDrugs       Date:  2015-08       Impact factor: 5.807

9.  Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody.

Authors:  Mahiuddin Ahmed; Ming Cheng; Irene Y Cheung; N K Cheung
Journal:  Oncoimmunology       Date:  2015-04-27       Impact factor: 8.110

10.   De novo isolation of antibodies with pH-dependent binding properties.

Authors:  Pauline Bonvin; Sophie Venet; Gaëlle Fontaine; Ulla Ravn; Franck Gueneau; Marie Kosco-Vilbois; Amanda Ei Proudfoot; Nicolas Fischer
Journal:  MAbs       Date:  2015       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.